GATC Health Announces New Master Services Agreement with Public Clinical-Stage Biopharmaceutical Company

Irvine, CA – February 23, 2026 – GATC Health Corp (“GATC”), a leader in AI‑driven analytics for drug development and risk assessment, today announced that it has entered into a multi‑project Master Services Agreement with a publicly traded, clinical‑stage biopharmaceutical company focused on therapies for neuropsychiatric and related disorders. At the client’s request, its name is not being disclosed in this announcement.

Under the Agreement, GATC will deploy its Operon™ platform to generate four advanced analytical reports supporting the client’s development pipeline. Three Derisq™ reports will evaluate separate drug candidates before they advance into new or expanded clinical trials, providing comprehensive views of efficacy, safety, off‑target risks, and endpoint robustness to guide go/no‑go and trial‑design decisions. A fourth analysis will focus on a clinical‑stage program, delivering a detailed assessment intended to help the sponsor interpret and respond to regulatory feedback from the U.S. Food and Drug Administration (FDA), including issues raised in formal FDA communications.

“This collaboration demonstrates how AI‑powered analysis can both derisk future studies and help sponsors respond more effectively to regulatory questions,” said Jayson Uffens, Chief Technology Officer of GATC Health. “By running multiple Derisq assessments across different candidates, alongside a deep dive on an active clinical‑stage asset, we can deliver decision‑ready insights at critical inflection points for a sophisticated public‑company partner.”

The Agreement provides for an upfront payment, as well as success‑based contingent bonuses, aligning value creation for both parties.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform, Operon™, is generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit gatchealth.com.